Lu, XueminLu, Xin2024-01-042024-01-042022Lu X, Lu X. Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188702. doi:10.1016/j.bbcan.2022.188702https://hdl.handle.net/1805/37597Immune checkpoint blockade (ICB) as a powerful immunotherapy has transformed cancer treatment. The application of ICB to genitourinary malignancies has generated substantial clinical benefits for patients with advanced kidney cancer or bladder cancer, yet very limited response to ICB therapy was observed from metastatic castration-resistant prostate cancer. The efficacy of ICB in rare genitourinary tumors (e.g. penile cancer) awaits results from ongoing clinical trials. A potential barrier for ICB is tumor-infiltrating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) with their functions and mechanisms recently revealed. Preclinical studies suggest that successful therapeutic inhibition of PMN-MDSCs synergizes effectively with ICB to eradicate ICB-refractory genitourinary malignancies.en-USPublisher PolicyProstate cancerRenal cell carcinomaBladder cancerPenile cancerPenile squamous cell carcinomaPolymorphonuclear myeloid-derived suppressor cellImmunotherapyCXCR2Reactive nitrogen speciesArticle